Compare QUBT & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QUBT | ZLAB |
|---|---|---|
| Founded | 2001 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2019 | 2017 |
| Metric | QUBT | ZLAB |
|---|---|---|
| Price | $9.70 | $19.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $17.50 | ★ $49.60 |
| AVG Volume (30 Days) | ★ 17.4M | 1.0M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 84.93 | 38.46 |
| EPS | ★ N/A | N/A |
| Revenue | $682,000.00 | ★ $460,156,000.00 |
| Revenue This Year | $3,210.56 | $9.75 |
| Revenue Next Year | $51.26 | $26.03 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 82.84 | 15.33 |
| 52 Week Low | $6.18 | $15.96 |
| 52 Week High | $25.84 | $41.20 |
| Indicator | QUBT | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 46.99 | 57.81 |
| Support Level | $9.60 | $16.78 |
| Resistance Level | $10.17 | $19.41 |
| Average True Range (ATR) | 0.83 | 0.71 |
| MACD | -0.12 | 0.24 |
| Stochastic Oscillator | 33.52 | 97.69 |
Quantum Computing Inc is an integrated photonics and non-linear quantum optics company to develop and deliver machines for quantum computing, reservoir computing, and remote sensing, imaging, and cybersecurity applications based on patented and proprietary photonics technology. Its products are designed to operate at room temperature and low power at an affordable cost. The Company's portfolio of core technologies and products offers capabilities in the areas of high-performance computing, artificial intelligence, and cybersecurity, as well as remote sensing applications.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.